Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation. Our choice today is laced with traces of cocoa. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today and, of course, do keep in touch …
Sanofi (SNY) agreed to pay $11.6 billion for Bioverativ, a spinoff from Biogen (BIIB) that will catapult the big drug maker into the market for treatments for rare blood disorders. The deal is the biggest by Sanofi in several years after failed efforts to buy Medivation and Actelion, and comes as the French drug maker struggles to offset declines for its best-selling Lantus insulin and its struggling diabetes franchise.
About the Author Reprints
http://alph.st/bce19e98 Celgene makes the second multi-billion dollar acquisition in 2018. Juno, after the last week’s 50% hike, again shooting up after the buyout confirmation news